Merck's PD-1 Inhibitor Keytruda Approved by U.S. FDA for Cervical Cancer Treatment

MSD announced on January 12 local time that the U.S. Food and Drug Administration (FDA) has approved MSD's PD-1 inhibitor Keytruda in combination with chemoradiotherapy (CRT) for the treatment of patients with stage III-IVA cervical cancer as defined by the International Federation of Gynecology and Obstetrics (FIGO) 2014. (Cailian Press)Original Link